Infection and Malignancy in Transplantation
Infection and malignancy are the two dominant non-rejection complications that follow organ transplantation, and both arise from the same underlying cause: the sustained immunosuppression that is required to keep an allograft from being rejected. By blunting the recipient's immune surveillance, immunosuppression simultaneously lowers the threshold for opportunistic infection and weakens the control of oncogenic viruses and emerging tumours, making these two problems the principal long-term threats to recipient survival.
Definition
Infection and malignancy in transplantation is the body of knowledge concerned with the infectious and neoplastic consequences of the immunosuppressed state in transplant recipients, encompassing the epidemiology, mechanisms, recognition, and prevention of opportunistic infection and of transplant-associated cancers.
Scope
This area orients the reader to the spectrum of infectious and neoplastic complications seen after solid-organ transplantation: opportunistic infections and their characteristic timeline, cytomegalovirus as the prototypic transplant pathogen, de novo malignancies and post-transplant lymphoproliferative disorder, and the prophylaxis and monitoring strategies that aim to prevent these events. It is a reference-educational overview of how immunosuppression reshapes infection and cancer risk, not a protocol for managing individual patients.
Sub-topics
Core questions
- How does the intensity and type of immunosuppression shape the risk of opportunistic infection and of de novo cancer?
- What is the characteristic temporal sequence of infections after transplantation, and why does it follow that pattern?
- Which oncogenic viruses drive transplant-associated malignancy, and how does loss of immune surveillance permit them?
- How can infection be prevented or detected early without over-suppressing or under-immunizing the recipient?
Key concepts
- Net state of immunosuppression
- Timeline of post-transplant infection
- Opportunistic infection
- Oncogenic (tumour) viruses and loss of immune surveillance
- Donor-derived and reactivated latent infection
- Risk-stratified prophylaxis and monitoring
- Trade-off between rejection and infection/cancer risk
Mechanisms
Maintenance immunosuppression suppresses T-cell and, to varying degrees, B-cell function to prevent allograft rejection; the same suppression diminishes the immune surveillance that normally contains latent pathogens and transformed cells. Fishman's concept of the net state of immunosuppression frames infection risk as the product of the immunosuppressive regimen together with host factors and environmental exposures, and explains the recognizable post-transplant timeline in which nosocomial and donor-derived infections dominate early, opportunistic and viral infections (including cytomegalovirus) emerge in the intermediate period, and community-acquired and late viral processes predominate thereafter. The same impaired surveillance allows oncogenic viruses to drive proliferation, so that Epstein-Barr virus underlies much post-transplant lymphoproliferative disorder and human herpesvirus 8 and human papillomavirus contribute to other transplant-associated cancers; population data confirm that recipients carry a broadly elevated and virus-skewed cancer incidence.
Clinical relevance
These complications account for a large share of post-transplant morbidity and of deaths with a functioning graft, which is why infectious-disease surveillance and cancer screening are integral parts of transplant follow-up. This entry describes how immunosuppression generates infection and cancer risk and how prevention is conceived at the population level; it is educational and does not provide drug regimens or individualized management.
Epidemiology
Solid-organ transplant recipients experience cancer at roughly twice the rate of the general population, with markedly higher risks for virus-associated and immune-related tumours, as shown in a large US registry linkage by Engels and colleagues and in a meta-analysis by Grulich and colleagues that found a cancer-risk pattern closely paralleling that of people with HIV/AIDS. Infectious risk likewise tracks the degree of immunosuppression and follows a reproducible temporal sequence described in the transplant infectious-disease literature.
History
As immunosuppressive regimens grew more effective from the 1980s onward and graft survival improved, attention shifted from acute rejection toward the longer-term costs of sustained immunosuppression. Fishman and Rubin's framing of the net state of immunosuppression and the post-transplant infection timeline became a standard organizing model, while large registry studies in the 2000s and 2010s quantified the excess and virus-driven cancer burden, consolidating infection and malignancy as the central long-term concerns of transplant medicine.
Key figures
- Jay A. Fishman
- Eric A. Engels
- Andrew E. Grulich
- Philip F. Halloran
Related topics
Seminal works
- fishman-2007
- engels-2011
- grulich-2007
Frequently asked questions
- Why are transplant recipients especially prone to both infection and cancer?
- Both stem from the same source: lifelong immunosuppression given to prevent rejection also weakens the immune surveillance that normally contains latent infections and abnormal cells, so the very treatment that protects the graft raises infection and cancer risk.
- Why do different infections appear at different times after a transplant?
- Post-transplant infections follow a recognizable timeline driven by the changing balance of surgical, donor-derived, and immunosuppression-related risks, so the dominant pathogens differ between the early, intermediate, and late periods.